Received Apr 20, 2026
Reports are unverified and do not show that a vaccine caused an event. Full disclaimer
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | 1 | AMVB079A | — |
Wrong diluent to reconstitute; Wrong diluent to reconstitute; This non-serious case was reported by a other health professional via call center representative and described the occurrence of wrong solution used in drug reconstitution in a 16-year-old female patient who received Men ACWY-CRM NVS (Menveo) (batch number AMVB079A, expiry date 31-MAY-2026) for prophylaxis. On 10-APR-2026, the patient received the 1st dose of Menveo. On 10-APR-2026, an unknown time after receiving Menveo, the patient experienced wrong solution used in drug reconstitution (Verbatim: Wrong diluent to reconstitute) and inappropriate dose of vaccine administered (Verbatim: Wrong diluent to reconstitute). The outcome of the wrong solution used in drug reconstitution and inappropriate dose of vaccine administered were not applicable. Additional Information: GSK Receipt Date: 10-APR-2026 The clinical coordinator reached to request data on the administration of Menveo (2 vial presentation) after it had been reconstituted with a diluent from their MMR vaccine. The vaccine administration facility was the same as primary reporter.; Sender's Comments: US-GSK-US2026050414:Same reporter